The present study was designed to determine whether *N 0 produced in vivo during the rejection of histoincompatible tissues might permit serum NOQ/N0 levels to serve as markers of a rejection reaction. Rat syngeneic and allogeneic liver, heart, bone marrow/spleen cell, small bowel, skin, and sponge matrix grafts were performed and the stable endproducts of N 0, NOQ/N0, were serially assayed in the serum of the grafted animals. A significant rise of serum NOQ/NO-levels in the allografted animals preceded the onset of clinical signs of rejection or graft-versus-host disease, with the exception of the skin and sponge matrix graft models, where elevated serum NO /NO-levels were never observed. In all transplant models, normal serum NO /NO-levels were observed at all times in animals that received syngeneic grafts. Furthermore, treatment ofallograft recipients with the immunosuppressive agents FK 506 or cyclosporine A inhibited N 0 production. Determination of serum creatinine levels demonstrated that the elevated serum NO /NO-levels were not caused by kidney dysfunction. Serum NOQ/NO-levels might be useful early serum markers of the initiation of a rejection reaction or graft-versushost disease when functional markers of graft dysfunction are not apparent. (J. Clin. Invest. 1992. 90:679-683.)
1. Abbreviations used in this paper: BN, Brown-Norway (rat); CsA, cyclosporine A; GVHD, graft-versus-host-disease; "N=O, nitric oxide; NO-/NO-, nitrite/nitrate; POD, postoperative day. role as endothelial derived relaxing factor has been clearly defined. Endothelial cells contain a constitutive enzyme generating small quantities ofN = 0, which, in turn, activates guanylate cyclase. This activation leads to elevated vascular and platelet levels of cyclic GMP inducing smooth muscle relaxation and platelet deaggregation (for review, see 1). Much larger amounts of N = 0 are generated by the nitric oxide synthase which can be induced by LPS and cytokines. In activated macrophages, 'N = 0 seems to be responsible for important aspects of antimicrobial activity, a subject that has been extensively studied (for review, see 2).
These findings prompted us to investigate the significance of N = 0 synthesis during the course of an immune response to alloantigen. We demonstrated that inhibition of rat splenocyte mixed lymphocyte reactions is caused by N = 0 production within these cultures (3) . Furthermore, we recently reported evidence that nitrite/nitrate (NO-/NO-) levels are elevated in the fluid surrounding rat sponge matrix allografts when compared to syngeneic grafts (4) . The present experiments were designed to determine whether N = 0 production accompanied organ allograft rejection and graft-versus-host disease (GVHD) in vivo, and whether this production could serve as a "marker" of this immune response. Therefore, the stable endproducts of N =0 synthesis, serum NOj/NO levels were measured in untreated and immunosuppressed rats, receiving liver, heart, small bowel, skin, sponge matrix, and bone marrow/spleen cell allografts.
Methods
Animals. Male Lewis (RTI'), Brown-Norway (BN) (RTP), and ACI (RTIP) rats weighing 180-240 g were purchased from Harlan Sprague Dawley, Inc., Indianapolis, IN. All animals were maintained on a 12-h light/dark cycle and fed commercially available rat chow and tap water ad lib.
Experimental design. Lewis rats always served as recipients of either allogeneic or syngeneic transplants. BN or ACI rats served as allogeneic organ or cell donors. For each transplant model, an untreated allogeneic and syngeneic grafted group was prepared. Additionally, groups of syngeneic and allogeneic grafted animals (with the exception ofsponge matrix and skin grafts) were treated with either Cyclosporine A (CsA) or FK 506. All Heterotopic heart transplantation was performed as previously described (6) . Heart grafts were palpated daily and rejection was established when complete cessation of the heartbeat occurred and was confirmed by direct inspection at laparotomy.
Bone marrow/spleen cell transplantation was performed as previously described (7 
Results
Liver grafts. Untreated Lewis recipients of BN liver allografts (n = 4) appeared healthy until POD 5-7, at which time reduced alertness, subsequent weight loss, icterus, and lethargy (POD 8-14) were observed. Gradual recovery from these symptoms was observed on POD 16-20, and the recipients appeared healthy again around POD 25. The serum NO /NO-levels of the allografted animals were significantly elevated on POD 5, 10, and 15, and normal values were observed on POD 25 (Fig.  1 ). In contrast, animals that received syngeneic grafts (n = 3) were healthy, and normal NO-/NO-levels were detected during the entire observation period.
When Lewis recipients of BN liver allografts (n = 3) were treated with FK 506 (0.5 mg/kg body wt per d) for 3 d, the animals were healthy and normal serum NO-/NO-levels were observed at all time intervals after grafting ( Fig. 1) . Evidence of rejection was not detected upon histologic examination of the allografts at necropsy on POD 34 (data not shown).
Heart grafts. The first clinical sign of BN heart allograft rejection in Lewis recipients (n = 4) (palpable weakened heartbeat) was observed between POD 5 and 7, with complete cessation of the heartbeat between POD 9 and 1 1. The serum NO-/ NO-levels of the allografted animals were significantly elevated on POD 5 and returned to baseline levels on POD 10 ( Fig. 2) . A normal heartbeat was detected in the syngeneic grafts (n = 4) at all time intervals, and serum NO-/NO-levels were not elevated at any time.
Lewis recipients of BN heart allografts (n = 4) treated with (Fig. 3 A) . The animals that received syngeneic grafts (n = 3) were healthy throughout the experiment, and normal NO /NO-serum levels were detected.
When Lewis recipients ofACI (n = 4) or Lewis (n = 3) small bowel grafts were treated with CsA (15 mg/kg body wt per day; POD 0-6 and POD 8-28 every other day), all animals were healthy until POD 45-50. Then diarrhea and successive weight loss occurred in the allograft recipients, and the animals were killed at a mean of66±4.6 d. The serum NO-/NO-levels ofthe allografted animals were slightly elevated on POD 30 and signif- icantly elevated on POD 40 and 50, when compared to the values in animals that received syngeneic grafts (Fig. 3 B) . Histologic examination of the transplanted tissue on POD 40 (n = 3), when allografted animals were still clinically healthy but the serum NO /NO-levels were elevated, provided evidence of a mild chronic cellular rejection (data not shown).
Skin grafts. The onset of skin allograft rejection (erythema and epithelial necrosis) was observed between POD 7 and 9 (n 5) and complete rejection (i.e., total necrosis of the epidermis) was detected between POD 10 and 13. Syngeneic skin grafts (n = 3) were accepted without complication. Serum NO-/NO-levels, determined on POD 5, 8, 12, and 16, were not elevated in either group (Table I) .
Sponge matrix grafts. As previously described, donor-specific cytotoxic T lymphocytes at the graft site in this model were first detected on POD 6, peaked between POD 7-8, and waned by POD 10 (4). Serum NO-/NO-levels, determined on POD 4, 6, 8, and 10, were not elevated in either group (Table I) .
Bone marrow/spleen cell grafts. The first clinical signs of GVHD in the Lewis recipients of ACI allografts (n = 8) were observed between POD 7 and 9. The animals developed diarrhea, lost weight, and when moribund, were killed at a mean of 21.3±1.7 d. The NO-/NO-serum levels of the allografted animals were significantly elevated on POD 5, days before the first clinical signs of GVHD were observed. The levels remained elevated until the animals were killed (Fig. 4 A) . Lewis rats, which had been irradiated and reconstituted syngeneically (n = 6) remained healthy and NO-/NO-serum levels remained normal throughout the experiment.
FK 506(1 mg/kg body wt per d) was administered to Lewis recipients ofsyngeneic (n = 8) bone marrow/spleen cell inocula on days 0-6. NO-/NO3 levels, monitored at various intervals until day 45, remained within normal range. FK 506 was also administered to Lewis recipients of allogeneic bone marrow/ spleen cell inocula on days 0-6 (n = 10) or days 7-21 (n = 7) postgrafting. Administration ofFK 506 on days 0-5 resulted in a delayed elevation of serum NO-/NO-levels when compared to untreated animals. Administration of FK 506 on days 7-12 postgrafting resulted in a dramatic decrease in serum NO-/ NO3 levels from pretreatment values on day 7 to values obtained on day 13, when the animals had received FK 506 for 7 d (Fig. 4 B) . As described by Markus et al. (7) , FK 506 treatment of Lewis recipients of ACI allogeneic bone marrow/ spleen cell inocula, results in detection of donor cell (ACI) engraftment in these recipients on POD 30 and prolonged survival compared to untreated animals (data not shown).
Discussion
The discovery that N 0 is produced by cells of the monocyte-macrophage lineage in response to inflammatory cyto- kines such as IL-1, tumor necrosis factor, and IFNy initiated our investigation into the possible immunomodulating effects of N 0 on the allograft response. Initially, we showed that the inhibition of lymphocyte proliferation in rat splenocyte mixed lymphocyte cultures coincided with high NO/NO levels in the culture supernatants, and that this inhibition was reversed by the addition of NG-monomethyl-L-arginine (NMA), the competitive inhibitor of N =0 synthesis (3). In a subsequent study, we showed that cells infiltrating sponge matrix allografts produce more N 0 spontaneously than cells which have infiltrated a syngeneic graft, and that allospecific cytolytic activity of cultured allograft infiltrating lymphocytes was observed only when NMA was added to the cultures. Additionally, macrophages, which have been shown in a number of studies to be a major subpopulation of graft infiltrating cells ( 12) , were responsible for most of the 'N 0 produced by the sponge graft infiltrating cells (4) . The N 0-induced inhibition of lymphocyte proliferation has subsequently been confirmed by others using mitogen-stimulated rat splenocyte cultures (13, 14) . Barbul has demonstrated that in lymphocytes, L-arginine is converted to picomolar quantities of 'N -0, which may be essential for lymphocyte responses (15) . In contrast, the large amount of 'N 0 produced in macrophage lymphocyte cocultures inhibits lymphocyte proliferation (3, 4, 13, 14, 16) . In all culture systems studied thus far, including the rat splenocyte mixed lymphocyte reaction and rat sponge allograft infiltrating cells cultured with alloantigen, IL-2 production is detected and the inhibition of T lymphocyte proliferation occurs because T cells are unable to use the cytokines that are produced (3, 16).
The present communication demonstrates for the first time that total body N O production is increased during the rejection of vascularized organ allografts and in GVHD. In all vascularized allograft models and the GVHD model, a significant rise in serum NO-/NO-levels was detected before clinical signs of rejection or GVHD were observed. In the BN to Lewis liver allograft model, a decrease of the serum NO-/NO-levels paralleled the dissolution of the rejection reaction. Furthermore, it is clear that N 0 production requires the initiation of an immune response, since elevated serum NO /NO-levels were never detected in animals that received syngeneic grafts. However, recipients of skin allografts and sponge matrix allografts showed no detectable change from normal serum NO-/ NO-levels before and during allograft rejection. Obvious differences such as size of the allograft and the fact that neither skin nor sponge matrix allografts are initially vascularized may account for the lack of elevation in serum NO /NO-levels. In the sponge allograft model, small but significantly increased NO /NO-levels were found in the fluid surrounding the allograft matrix (4), but rapid excretion of NO /NO-may prevent its detection in the serum. Since the number ofgraft infiltrating cells recovered from an acutely rejecting heart allograft in the rat (12) is comparable to the number of cells recovered from a sponge allograft (4) , the failure to find elevated serum NO-/ NO-in the recipients of sponge allografts may relate to the nature ofthe vascularization between the two allograft models.
The serum NO-/NO-ofthe recipients ofvarious organ and bone marrow/spleen cell allografts remained normal during therapy with CsA or FK 506. This finding confirms our previous in vitro observation, in which addition of FK 506 to cultures of sponge graft infiltrating cells plus alloantigen completely inhibited N -O production, presumably due to inhibition of T cell cytokine production by FK 506 (16) . However, when the immunosuppressive therapy was terminated and histologic evidence of recurring rejection or GVHD was ultimately detected (in the small bowel and the bone marrow/ spleen cell transplants), elevated NO-/NO-levels were detected. In contrast, FK 506-treated liver and heart allograft recipients not only maintained normal serum NO-/NO-levels, but also maintained normal graft function. Thus, these data suggest that the detection of elevated serum NO-/NOlevels in recipients of vascularized allografts correlates well with the rejection reaction. Serum NO-/NO-levels may possibly prove to be an early marker of graft rejection, but the clinical utility of such an assay is, as yet, untested. It is quite probable that endothelial cell derived N = 0 also plays a role in vascularized allograft rejection. However, the amount of N =0 produced via the constitutive pathway is quite small compared to the inducible pathway and thus is not likely to be a significant component of the serum NO-/NO-levels measured here.
Many reports now exist documenting increased serum NO-/NO-and/or elevated urinary excretion of NO-/NOafter administration of immunostimulatory agents such as LPS, Bacillus Calmette-Guerin, or C. parvum in rats and mice. Thus, it is clear that elevated NO /NO-levels are indicative of initiation of a cellular immune reaction, similar to elevated neopterin levels (17) 17] ). Several investigators reported that a rise in serum and urine neopterin levels was an early marker of a cellular immune response in some patients undergoing allograft rejection (reviewed in 17). It is therefore conceivable that the elevated NO-/NO-serum levels seen in our studies reflect the increased availability of 5,6,7,8-tetrahydrobiopterin, a necessary cofactor for N = 0 synthesis.
Using electron paramagnetic resonance (EPR) spectroscopy, which can directly detect N 0, bound, for example, to hemoglobin, Lancaster and Hibbs were able to prove that cytokine-activated macrophages possess the characteristic iron-nitrosyl signal, specific for N 0 (21). Subsequently, Drapier et al. demonstrated that the macrophage-derived N 0 can be detected in the mitochondria oftarget cells after coculture (22) , where it possibly exerts its known inhibitory effect on several mitochondrial enzymes (23) . In a recent study, we have observed that EPR-detectable N O is produced in a heart allograft rejection model and can be localized to the rejecting allograft and the blood, but not to other organ sites (24). Since we have previously shown in vitro that N 0 production during the response to alloantigen inhibits lymphocyte proliferation (3, 4, 16) , it is conceivable that 'N=O synthesis might be a regulatory effector mechanism in vivo also. However, whether the N O produced in vivo can in fact delay the rejection process by inhibiting lymphocyte function remains to be determined.
Serum NO/NO-levels may well prove to be a useful marker of the rejection of vascularized allografts and GVHD. The measurement of NOQ/NO-in serum and urine is simple and reliable, and may provide evidence of an even mild controlled rejection or GVHD, which otherwise would prove difficult to detect by conventional assays oforgan function or other methods of immunological monitoring. Whether NOj/NO3 levels will increase during viral or other opportunistic infections is presently unknown.
